Hydrogel-enabled, local administration and combinatorial delivery of immunotherapies for cancer treatment
Name
1-s2.0-S1369702123000688-main.pdf
Description
Published version
Size
2.11 MB
Format
Adobe PDF
Checksum (MD5)
147a8a87f78c0378e82c82bffd70c8c9
Author(s)
Erfani, Amir
Diaz, Antonio E
Doyle, Patrick S
Date Issued
May 2023
Journal
Materials Today
Publisher
Elsevier BV
Citation
Erfani, Amir, Diaz, Antonio E and Doyle, Patrick S. 2023. "Hydrogel-enabled, local administration and combinatorial delivery of immunotherapies for cancer treatment." Materials Today, 65.
Version
Final published version
Abstract
Throughout the last decade, interventions to engineer the immune system called immunotherapy have revolutionized the fields of oncology and autoimmune disease. Researchers are developing platforms that enable new modes of immunotherapy and expand the current limitations by incorporating non-intravenous delivery strategies. Recent advances in the immunotherapy include the use of chemokines to direct immune cells into tumors, alternative combinatorial therapies, and oncolytic viruses. Similarly, there have been significant breakthroughs in the design and understanding of new biocompatible hydrogel-based materials for diverse biomedical applications, including large molecule drug delivery. In this review, we discuss how hydrogel platforms can enable modes of immunotherapy that are otherwise not feasible. Despite the many pre-clinical successes of hydrogels for the delivery of immunotherapies for treatment of cancer, hydrogels still face challenges in getting to the clinic and eventually approved. Herein we examine the application of hydrogels in high concentration subcutaneous, intratumoral, peritumoral, intraperitoneal, intracranial, and pulmonary delivery of immunotherapies. By analyzing the results of many pre-clinical hydrogel-enabled immunotherapy studies, we describe that local hydrogel delivery is a promising approach to increase the efficacy and decrease systemic toxicities of immunotherapies. We also discuss the application of hydrogels for synergistic combinatorial immunotherapy. Furthermore, we summarize the advancements and obstacles in local intratumoral administration and sustained release of immunotherapy-loaded hydrogels. Finally, we discuss challenges in the translational research, clinical development, and manufacturing of hydrogels which must be addressed to advance the field.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.mattod.2023.03.006
